^
    1d
    Site-specific propynylation modification of apigeninidin enhances anti-cervical cancer activity by targeting PARP-1. (PubMed, Bioorg Chem)
    In vitro experiments further demonstrated that APN-A can dramatically reduce the viability of cervical cancer cells, inhibited cell proliferation and migration, and synergistically potentiate the antitumor efficacy of 5-fluorouracil (5-FU). In addition, chemical proteomics enrichment analyses indicated that APN-A shows its antitumor effects primarily by targeting and inhibiting processes such as DNA replication and protein transcription-translation in cancer cells via targeting proteins such as PARP-1, EIF3J, and TCEA1. These findings provide a methodological reference and mechanistic insight for the propynyl modification of APN, and highlight its potential applications in the food industry and drug development.
    Journal
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    5-fluorouracil
    1d
    OSMR coordinates a self-perpetuating circuit linking chemoresistance and neutrophil-driven immunosuppression in gastric cancer. (PubMed, Neoplasia)
    Therapeutically, OSMR neutralization with vixarelimab synergized with fluorouracil to overcome chemoresistance and reinstate anti-tumor immunity in GC preclinical models. Our findings establish OSMR as a molecular linchpin connecting intrinsic tumor survival pathways (PI3K/CCNE2) with extrinsic immunosuppressive reprogramming (BMP5/TANs/CD8+T cells), providing a clinically actionable target to overcome treatment resistance in GC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CCNE2 (Cyclin E2) • OSMR (Oncostatin M Receptor)
    |
    PD-L1 expression
    |
    5-fluorouracil
    2d
    ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases (clinicaltrials.gov)
    P2, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    2d
    LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation (clinicaltrials.gov)
    P1/2, N=99, Not yet recruiting, Luye Pharma Group Ltd.
    New P1/2 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium
    2d
    LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=43, Completed, University Hospital, Grenoble | Active, not recruiting --> Completed
    Trial completion
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    5-fluorouracil • oxaliplatin • irinotecan • NP137 • levoleucovorin calcium
    2d
    Curcumin in Combination With 5FU for Colon Cancer (clinicaltrials.gov)
    P1, N=15, Terminated, Baylor Research Institute | Unknown status --> Terminated; PI-Initiated study; PI requested closure
    Trial termination
    |
    5-fluorouracil
    2d
    Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU (clinicaltrials.gov)
    P2, N=583, Recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    2d
    SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P1, N=25, Recruiting, University of Miami | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    2d
    PANACHE01-PRODIGE48 Study: Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=153, Completed, University Hospital, Rouen | Unknown status --> Completed
    Trial completion
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    2d
    RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=28, Completed, Canadian Cancer Trials Group | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha)
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation
    |
    Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306) • camonsertib (RP-3500)
    2d
    Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov)
    P2, N=56, Recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • Focus V (anlotinib) • Andewei (benmelstobart) • Onivyde (nanoliposomal irinotecan)
    2d
    A neural network model delivers a highly prognostic protein signature in cancer stem cells that identifies relapse in stage III colorectal cancer patients. (PubMed, bioRxiv)
    Particularly, we found overexpression of GLUT1, FLIP and downregulation of BAX, BAK, MLKL and CDX2 proteins in the cancer stem cell of early recurrence samples.We built a neural network based on the cancer stem cell protein signature (BAX, MLKL, FLIP, GLUT1 and CDX2 proteins) that delivers a high-performance prognostic classifier.How this study might affect research, practice or policy: Our results propose a clinically promising prognostic tool based on a five-protein stem cell signature that outperforms existing clinical and proposed transcriptomic based signatures for separation between risk groups.Moreover, our five-protein signature markers not only predict stem cell chemotherapy resistance and therefore tumour recurrence but also suggest potential therapeutic strategies. For instance, this approach could guide combinatorial treatments at high risk of chemoresistance, such as incorporating small molecule inhibitors targeting FLIP (currently in discovery phase) and GLUT1 (already under preclinical trial evaluation).
    Journal
    |
    BAX (BCL2-associated X protein) • CDX2 (Caudal Type Homeobox 2) • MLKL (Mixed Lineage Kinase Domain Like Pseudokinase) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    5-fluorouracil